Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus
BackgroundFor long-term hospitalized patients suffering from schizophrenia, metabolic disease and hyperprolactinemia (HPRL) are common comorbidities. This article is aimed at analyzing the factors influencing comorbid type 2 diabetes mellitus (T2DM) on prolactin (PRL) levels in long-term hospitalize...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1034004/full |
| _version_ | 1811182054470057984 |
|---|---|
| author | Junhong Zhu Junhong Zhu Huijuan Wang Shaoyun Huang Shaoyun Huang Yingying Zhang Xuebing Liu Xuebing Liu Yi Li Yi Li Jun Ma Jun Ma |
| author_facet | Junhong Zhu Junhong Zhu Huijuan Wang Shaoyun Huang Shaoyun Huang Yingying Zhang Xuebing Liu Xuebing Liu Yi Li Yi Li Jun Ma Jun Ma |
| author_sort | Junhong Zhu |
| collection | DOAJ |
| description | BackgroundFor long-term hospitalized patients suffering from schizophrenia, metabolic disease and hyperprolactinemia (HPRL) are common comorbidities. This article is aimed at analyzing the factors influencing comorbid type 2 diabetes mellitus (T2DM) on prolactin (PRL) levels in long-term hospitalized patients suffering from schizophrenia.MethodsThis study included 378 long-term hospitalized patients with schizophrenia. Common metabolic markers and PRL levels of included samples were collected, and the severity of psychopathology was assessed using the Positive and Negative Symptoms Scale (PANSS). Based on the patients with or without T2DM, the samples were divided into two groups. The differences in clinical parameters between the two groups were compared, and the effects of the parameters on the PRL levels were analyzed.ResultsCompared with non-DM patients, the patients in the DM subgroup had lower PRL levels (P < 0.0001) and rather severe psychiatric symptoms (P = 0.016). Female, treated by risperidone, and high levels of triglyceride (TG) were faced with risk for HPRL (B = 26.31, t = 5.39, P < 0.0001; B = 19.52, t = 4.00, P < 0.0001; B = 2.71, t = 2.31, P = 0.022, respectively). Meanwhile, co-morbid DM and aripiprazole treatment were protective factors (B = 15.47, t = 3.05, P = 0.002; B = –23.77, t = –2.47, P = 0.014; respectively). Ultimately, in the DM subgroup, the dose of metformin was found to be a protective factor for HPRL (B = –0.01, t = –1.46, P = 0.047), while female and aripiprazole were risk factors (B = 16.06, t = 3.26, P = 0.001; B = 20.13, t = 2.57, P = 0.011; respectively).ConclusionAripiprazole is a protective factor for HPRL in long-term hospitalized patients, whereas the female is a risk factor. Metformin is beneficial in reducing PRL levels in patients with co-morbid DM. More aggressive and effective interventions are required for preventing adverse drug reactions in women and patients with co-DM. |
| first_indexed | 2024-04-11T09:26:48Z |
| format | Article |
| id | doaj.art-503fa030564d43af9fd3bc0ca215dc0c |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-11T09:26:48Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-503fa030564d43af9fd3bc0ca215dc0c2022-12-22T04:32:00ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402022-10-011310.3389/fpsyt.2022.10340041034004Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitusJunhong Zhu0Junhong Zhu1Huijuan Wang2Shaoyun Huang3Shaoyun Huang4Yingying Zhang5Xuebing Liu6Xuebing Liu7Yi Li8Yi Li9Jun Ma10Jun Ma11Department of Psychiatry, Wuhan Mental Health Center, Wuhan, ChinaWuhan Hospital for Psychotherapy, Wuhan, ChinaSuzhou Guangji Hospital, Suzhou, ChinaDepartment of Psychiatry, Wuhan Mental Health Center, Wuhan, ChinaWuhan Hospital for Psychotherapy, Wuhan, ChinaXinyang Vocational and Technical College, Xinyang, ChinaDepartment of Psychiatry, Wuhan Mental Health Center, Wuhan, ChinaWuhan Hospital for Psychotherapy, Wuhan, ChinaDepartment of Psychiatry, Wuhan Mental Health Center, Wuhan, ChinaWuhan Hospital for Psychotherapy, Wuhan, ChinaDepartment of Psychiatry, Wuhan Mental Health Center, Wuhan, ChinaWuhan Hospital for Psychotherapy, Wuhan, ChinaBackgroundFor long-term hospitalized patients suffering from schizophrenia, metabolic disease and hyperprolactinemia (HPRL) are common comorbidities. This article is aimed at analyzing the factors influencing comorbid type 2 diabetes mellitus (T2DM) on prolactin (PRL) levels in long-term hospitalized patients suffering from schizophrenia.MethodsThis study included 378 long-term hospitalized patients with schizophrenia. Common metabolic markers and PRL levels of included samples were collected, and the severity of psychopathology was assessed using the Positive and Negative Symptoms Scale (PANSS). Based on the patients with or without T2DM, the samples were divided into two groups. The differences in clinical parameters between the two groups were compared, and the effects of the parameters on the PRL levels were analyzed.ResultsCompared with non-DM patients, the patients in the DM subgroup had lower PRL levels (P < 0.0001) and rather severe psychiatric symptoms (P = 0.016). Female, treated by risperidone, and high levels of triglyceride (TG) were faced with risk for HPRL (B = 26.31, t = 5.39, P < 0.0001; B = 19.52, t = 4.00, P < 0.0001; B = 2.71, t = 2.31, P = 0.022, respectively). Meanwhile, co-morbid DM and aripiprazole treatment were protective factors (B = 15.47, t = 3.05, P = 0.002; B = –23.77, t = –2.47, P = 0.014; respectively). Ultimately, in the DM subgroup, the dose of metformin was found to be a protective factor for HPRL (B = –0.01, t = –1.46, P = 0.047), while female and aripiprazole were risk factors (B = 16.06, t = 3.26, P = 0.001; B = 20.13, t = 2.57, P = 0.011; respectively).ConclusionAripiprazole is a protective factor for HPRL in long-term hospitalized patients, whereas the female is a risk factor. Metformin is beneficial in reducing PRL levels in patients with co-morbid DM. More aggressive and effective interventions are required for preventing adverse drug reactions in women and patients with co-DM.https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1034004/fulllong-term hospitalizedchronicschizophreniadiabetes mellitusmetabolic indicatorsprolactin |
| spellingShingle | Junhong Zhu Junhong Zhu Huijuan Wang Shaoyun Huang Shaoyun Huang Yingying Zhang Xuebing Liu Xuebing Liu Yi Li Yi Li Jun Ma Jun Ma Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus Frontiers in Psychiatry long-term hospitalized chronic schizophrenia diabetes mellitus metabolic indicators prolactin |
| title | Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus |
| title_full | Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus |
| title_fullStr | Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus |
| title_full_unstemmed | Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus |
| title_short | Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus |
| title_sort | factors influencing prolactin levels in chronic long term hospitalized schizophrenic patients with co morbid type 2 diabetes mellitus |
| topic | long-term hospitalized chronic schizophrenia diabetes mellitus metabolic indicators prolactin |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1034004/full |
| work_keys_str_mv | AT junhongzhu factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT junhongzhu factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT huijuanwang factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT shaoyunhuang factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT shaoyunhuang factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT yingyingzhang factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT xuebingliu factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT xuebingliu factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT yili factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT yili factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT junma factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus AT junma factorsinfluencingprolactinlevelsinchroniclongtermhospitalizedschizophrenicpatientswithcomorbidtype2diabetesmellitus |